

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 3153.00452	
In Re Application Of: Ruitang Deng et al.						
Application No. 10/672,489	Filing Date 09/26/2003	Examiner Unknown	Customer No. 48924	Group Art Unit 1614	Confirmation No. 8264	
Title: DNA VACCINE AGAINST FELINE IMMUNODEFICIENCY						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);						
OR						
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

3153.00452

In Re Application: **Wuitang Deng, et al.**

JAN 14 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/672,489	09/26/2003	Unknown	48924	1614	8264

Title: **DNA VACCINE AGAINST FELINE IMMUNODEFICIENCY****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **11-1449** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date)

Signature of Person Mailing Correspondence

MARIE M. LALLY

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

KENNETH I. KOHN
KOHN & ASSOCIATES, PLLC
30500 NORTHWESTERN HWY., SUITE 410
FARMINGTON HILLS, MICHIGAN 48334
(248) 539-5050

Dated: **JANUARY 10, 2005**

CC:




MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 3153.00452		Application Number 10/672,489	
				Applicant Deng, et al.			
				Filing Date 09/26/2003		Group Art Unit	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,177,014	01-1993	O'Connor et al.	435	188		
*	5,833,883	11-1998	Wardley et al.	424	208.1		
*	6,004,799	12-1999	Luciw et al.	435	236		
*	6,300,118 B1	10-2001	Chavez et al.	435	252.3		
*	6,348,196 B1	02-2002	Audonnet et al.	424	202.1		
	6,383,765	05-2002	Andersen et al.	435	7.92		
FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
*	WO 9530019	11-1995	PCT				
*	WO 9640268	12-1996	PCT				
*	WO 9732983	09-1997	PCT				
*	WO 9803660	01-1998	PCT				
*	WO 9821354	05-1998	PCT				
*	WO 9840493	09-1998	PCT				
*	WO 9840957	09-1998	PCT				
*	0997529A2	08-1999	EP				
*	2751223A1	07-1996	FR				
OTHER DOCUMENTS <i>(Including Author, Title, Date Pertinent Pages, Etc.)</i>							
*		Andresson et al., Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virol. 1993, Vol. 193, pages 89-105. See entire document.					
*		Baldinotti, et al., J. Virol., Vol. 68:4572-5479 (1994)					
*		Baumberger, et al., AIDS, 7:S59-S64 (1993)					
*		Bishop, et al., Vaccine, Vol. 14:1243-1250 (1996)					
*		Boyer, et al., Protection of Chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination, Nature Medicine, Vol 3, Numbers 5, Pages 526-532, May 1997.					
*		Cox et al. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virol. 1993, Vol. 195, pages					



	845-850. See entire document.
	Cuisinier, et al., Vaccine. Vol. 15:1085-1094 (1997)
	Cuisinier, et al., Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection, Vaccine 17, p 415-425, Elsevier Science Ltd. (1999)
*	Diehl, et al., J. Virol., Vol. 69:2328-2332 (1995)
*	Diehl, et al., J. Virol., Vol. 70:2503-2507 (1996)
*	Elyar, et al., Vaccine, Vol. 15:1537-1444 (1997)
*	Franchini et al. Highly attenuated HIV type 2 recombinational poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macques. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, Pages 909-920. See entire document.
*	Gonda et al. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res. 1994, Vol. 32, pages 155-181. See entire document.
*	Hoesie, et al., DNA Vaccination Affords Significant Protection against Feline Immunodeficiency Virus Infection without inducing Detectable Antiviral Antibodies, Journal of Virology, Vo. 72, No. 9, p. 7310-7319, Sept. 1998
*	Okuda et al. Induction of potent humoral and cell-mediated immune response following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, pages 933-943. See entire document.
*	Olmsted, et al., Molecular cloning of feline immunodeficiency virus. Proc. Natl. Acad. Sci. USA. April 1989, Vol. 86, pages 2448-2452. See entire document.
*	Pincus et al. Poxvirus-based vectors as vaccine candidates. Biologicals. 1995, Vol. 23, pages 159-164. See entire document.
*	Saltarelli et al. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virol. 1990, Vol. 179, pages 347-364. See entire document.
*	Von Schwedler, et al., Retroviral-Mediated Expression of FIV Envelope/Rev Induces CD8+ CTL Response in Mice, Intervirology 1997; 40:271-276.
*	Wardley et al. The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J. Gen. Virol. 1992, Vol. 73, pages 1811-1818. See entire document.
*	Whetter, et al., Equine infectious anemia virus derived from a molecular clone persistently infects horses. J. Virol. December 1990, Vol. 64, No. 12, pages 5750-5756. See entire document.
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

*Copies of all of the references cited herein were previously provided and considered by the Examiner during the prosecution of the parent application, now U.S. Patent No. 6,667,298.